Torrent Pharmaceuticals Ltd · NSE:TORNTPHARM

Torrent Pharmaceuticals — Q3 FY2013-14 Earnings Presentation

18 slides from Torrent Pharmaceuticals's earnings presentation, 2014

  1. Slide 1: Investor Presentation Q3 FY 2013-14

    Investor Presentation Q3 FY 2013-14 1

  2. Slide 2: Caveat

    Caveat This information may contain certain forward-looking statements/ details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expre

  3. Slide 3: Contents

    Contents 1. Performance Highlights 2. Financials 3. Business Segments • India • International 4. Facilities – Expansion Plan

  4. Slide 4: Q3 FY14 Highlights

    Q3 FY14 Highlights • Revenues at ` 1015 Cr vs. ` 797 Cr, growing at 27%; • India formulation market growing at 15% & • International operations growing at 41%; Constant currency growth of 25% • USA & European markets key contributors to growth • PBT at ` 188 Cr vs. ` 143 Cr in Q3 FY 14; showing grow

  5. Slide 5: Financials

    Financials 5

  6. Slide 6: Revenue Progression

    Revenue Progression ` Cr Q3 Q3 Particulars 12-13 11-12 13 - 14 12 - 13 India 296 258 1,024 909 Gwth % 15% 13% International 637 450 1,834 1,482 Gwth % 42% 24% Brazil 147 117 502 477 Europe (Includes Heumann) 248 156 650 542 USA 148 92 355 216 ROW* 95 86 327 247 Contract Manufacturing 76 75 300 296 G

  7. Slide 7: P&L

    P&L ` Cr Q3 Q3 Particulars 12-13 11-12 13 - 14 12 - 13 Revenues 1,015 797 3,212 2,696 COGS 318 246 926 863 % Revenues 31% 31% 29% 32% SG&A Spend 283 248 965 778 % Revenues 28% 31% 30% 29% Employee Cost 179 152 623 534 % Revenues 18% 19% 19% 20% EBITDA 235 151 698 522 % Revenues 23% 19% 22% 19% Forex

  8. Slide 8: Balance Sheet

    Balance Sheet ` Cr Particulars 31-Mar-13 % 31-Dec-13 % ∆ EQUITY AND LIABILITIES Shareholders funds 1,422 69% 1,732 69% 310 Minority Interest 0 0% 0 0% 0 Non-current liabilities 651 31% 796 31% 145 TOTAL 2,073 100% 2,528 100% 455 ASSETS Net Fixed Assets 1,105 53% 1,362 54% 257 Loans & Advances 63 3%

  9. Slide 9: Business Segment: India

    Business Segment : India 9

  10. Slide 10: India

    India ` Cr Q3 Q3 India 12-13 11-12 13 - 14 12 - 13 Revenues 296 258 1024 909 % Growth 15% 13% 9% • Q3 FY 14 Highlights • IPM growth: 5%, Covered Market growth: 5%, Torrent growth: 12% • Torrent 9th largest contributor to IPM’s incremental value • Growth drivers • Brand Building by focusing on the Br

  11. Slide 11: Business Segment: International

    Business Segment : International 11

  12. Slide 12: Brazil

    Brazil ` Cr Q3 Q3 Brazil 12-13 11-12 13 - 14 12 - 13 Revenues 147 117 502 477 % Growth 26% 5% 34% • Q3 FY 14 Highlights • Constant currency growth at 22%. • Branded Generics ~ 17%; Generic Generic ~ 5% • Covered Market Growth (excluding Government reimbursement programme) is 10%, Torrent growth 9% a

  13. Slide 13: USA

    USA ` Cr Q3 Q3 USA 12-13 11-12 13 - 14 12 - 13 Revenues 148 92 355 216 % Growth 61% 64% 89% • Q3 FY 14 Highlights • Constant currency growth 41% • Duloxetine (Cymbalta) launched in the Quarter under FTF status having a market share of around 7% to 8%. • 46 ANDA approved (inc. 6 tentative approvals)

  14. Slide 14: Europe

    Europe ` Cr Q3 Q3 Europe 12-13 11-12 13 - 14 12 - 13 Revenues 248 156 650 542 % Growth 59% 20% 16% • Q3 FY 14 Highlights • Euro revenue growth – 32% • Heumann & Romania key contributors to growth • Growth Drivers • New Products going off patent and Therapy coverage expansion in Heumann • Growing pro

  15. Slide 15: ROW

    ROW ` Cr Q3 Q3 ROW 12-13 11-12 13 - 14 12 - 13 Revenues 95 86 327 247 % Growth 10% 91% 16% • Q3 FY14 Highlights • Revenue de growth of 1% on constant currency basis. • Growth Drivers • Middle East/ Africa Region Delivering the growth being an upcoming market • Continuous registration of new products

  16. Slide 16: Facilities – Expansion Plan

    Facilities – Expansion Plan 16

  17. Slide 17: Facilities – Expansion Plan: Dahej SEZ

    Facilities – Expansion Plan Dahej SEZ • Nature: Formulation & API Capacity Enhancement • Project Cost: ` 1100 crores • Planned capacities: 80 TPA plus 14,000 million tablets / capsules p.a. • Timelines for completion: • Phase I: Project cost of ` 750 crores, First Regulatory Approval: Q2’14-15 • Pha

  18. Slide 18: Thank You

    Thank You 18

Torrent Pharmaceuticals — Q3 FY2013-14 Earnings Presentation on 6ix